Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

XBiotech Inc. XBIT

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$-45.5M
$-40.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

·
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2023 · Revenue 0.0 · Net income -24.6
250.0M500.0M
20132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2022 · Operating -860.1% · Net -820.4%
-500%
201320192025
ROE
FY2025 · ROE -28.2%
50%100%150%-50%
201320192025
Three returns, three denominators.

Each USD of equity lost 28 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -40.2
25.0M50.0M-25.0M-50.0M
201320192025
Net buybacks $M Dividends $M
FY2024 · Dividends · · Net buybacks -0.2
30M60M
201920202021202220232024

Total assetsUSD 150.1M
EquityUSD 140.3M
CashUSD 125.6M
Current ratio16.01×

Equity funds 94% of total assets.

The 13-year record

13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
XBIT, 13-year financial record
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B◌◌0.00.00.00.00.00.0◌◌◌◌◌
Operating income $B−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0
EBITDA $B−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.0
Income tax $B0.0−0.00.0−0.0−0.0−0.00.00.00.00.00.00.0◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.00.7−0.0−0.0−0.1−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.00.1−0.1−0.0−0.0−0.0−0.1−0.0−0.0−0.0
EPS, diluted $−1.49−1.26−0.81−1.08−0.58−0.3614.44−0.59−0.95−1.63−1.22−0.90−0.45
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout %———−0−431−00——————
ROE %−28.2−19.2−10.7−12.9−5.6−2.0167.8−41.6−55.6−65.1−46.3−62.7−97.1
Shares out B0.030.030.030.030.030.030.040.040.040.030.030.03◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 56 reconciliationsAUDITED

Reconciled in 13 of the 13 fiscal years we could check. 14 checks were skipped: the balance sheet is not tagged before 2014. 11 checks were skipped: revenue is not tagged before 2018. Six checks were skipped: EPS is not tagged before 2013.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code A1
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013

Share this section

Download image